Blood Pressure Management and Guideline‑Directed Therapies in HFpEF

Primary Blood‑Pressure Target

• In patients with HFpEF and cardiovascular risk factors, the recommended systolic/diastolic target is <130/80 mmHg; a less stringent target of <140/90 mmHg is acceptable for individuals aged ≥ 65 years. 1, 2

First‑Line Antihypertensive Additions

• ACE inhibitors or ARBs are endorsed by the American College of Cardiology as the preferred first‑line agents for hypertension control in HFpEF. They effectively lower blood pressure but do not confer the robust mortality benefit seen in HFrEF. 1
• Initiation should start with standard doses (e.g., lisinopril 10 mg daily or losartan 50 mg daily) and be titrated upward until the blood‑pressure target is achieved. 1

Diuretic Management

• Loop diuretics should be continued or optimized at the lowest effective dose to relieve fluid‑retention symptoms in HFpEF. 1
• When diuretic intensity is increased, clinicians must monitor for volume depletion, electrolyte disturbances, and worsening renal function. 3

Mineralocorticoid‑Receptor Antagonist (MRA) Consideration

• Spironolactone 12.5–25 mg daily may be added in appropriately selected patients (serum potassium < 5.0 mmol/L, creatinine < 2.5 mg/dL, eGFR > 30 mL/min) to potentially reduce HF hospitalizations. 1
• The TOPCAT trial demonstrated a modest reduction in HF hospitalizations (hazard ratio 0.83), although the composite primary endpoint did not reach statistical significance. 1
• Close monitoring of potassium and renal function is required when spironolactone is combined with ACE inhibitors or ARBs. 1

Metoprolol Optimization

• A metoprolol ER dose of 100 mg daily is reasonable but may be insufficient if blood pressure remains above target. 1
• Metoprolol succinate can be titrated up to 200 mg daily for additional blood‑pressure and heart‑rate control; however, evidence for mortality benefit in HFpEF is limited. 1

Monitoring and Safety

• Serum electrolytes (especially potassium), blood urea nitrogen, and creatinine should be checked when initiating or adjusting RAAS inhibitors and MRAs. 1
• Excessive diuresis can cause hypotension and prerenal azotemia, potentially limiting the use of other guideline‑directed therapies. This risk is highlighted in kidney‑disease guidance. 3

Common Pitfalls

• Beta‑blockers alone are insufficient for HFpEF management; the mortality benefit of beta‑blockade in HFpEF is weak, as shown in internal‑medicine evidence. 4, 1

All statements are supported by the cited references and reflect current guideline recommendations.

Management of Heart Failure with Preserved Ejection Fraction

Diagnosis and Initial Assessment

• The European Society of Cardiology recommends that HFpEF should be suspected in patients with typical heart failure symptoms with echocardiographic findings of normal ejection fraction (>40-50%) with impaired diastolic function 5
• Diagnostic workup should include natriuretic peptide measurement (BNP ≥35 pg/mL or NT-proBNP ≥125 ng/L) and transthoracic echocardiography with diastolic function assessment, as recommended by the European Heart Journal 5, 6

Pharmacological Management

• The American College of Cardiology recommends SGLT2 inhibitors, such as dapagliflozin or empagliflozin, regardless of diabetes status, as they reduce hospitalizations for heart failure (HR: 0.77-0.82) based on DELIVER and EMPEROR-PRESERVED trials 7
• The European Heart Journal suggests that diuretics, such as loop diuretics, should be used at the lowest effective dose for symptomatic relief of fluid retention, although they have not been shown to improve prognosis in HFpEF 5, 8, 9
• Mineralocorticoid Receptor Antagonists (MRAs), such as spironolactone, may be considered in selected patients, as they may reduce hospitalizations for heart failure based on regional data from the TOPCAT trial 7, 9

Management of Comorbidities

• The European Heart Journal recommends tight blood pressure control, with a target BP <140/90 mmHg, or <130/80 mmHg in patients with high cardiovascular risk, and suggests using ACE inhibitors, ARBs, and calcium channel blockers 5, 6, 9
• The American College of Cardiology suggests considering SGLT2 inhibitors as first-line therapy for diabetes, as they have been shown to reduce hospitalizations for heart failure 7, 6

Acute Decompensated HFpEF Management

• The European Heart Journal recommends intravenous loop diuretics as first-line for acute fluid overload, with an initial parenteral dose greater than or equal to the patient's chronic oral daily dose 10
• Monitoring of electrolytes, renal function, and blood pressure during diuresis is essential to avoid excessive diuresis leading to renal dysfunction 10

Initial Management of Heart Failure with Preserved Ejection Fraction (HFpEF) – Evidence‑Based Recommendations

Diagnostic Confirmation

• HFpEF diagnosis requires the presence of typical heart‑failure symptoms (e.g., dyspnea, orthopnea, peripheral edema) together with preserved left‑ventricular ejection fraction (LVEF ≥ 50%) on echocardiography. The American College of Cardiology (ACC) emphasizes both clinical and imaging criteria. 11
• Elevated natriuretic peptide levels are part of the diagnostic algorithm: BNP > 35 pg/mL (ambulatory) or > 100 pg/mL (hospitalized); NT‑proBNP > 125 pg/mL (ambulatory) or > 300 pg/mL (hospitalized).** These thresholds apply to patients with suspected HFpEF. 11
• Structural or functional cardiac abnormalities support the diagnosis: an E/e′ ≥ 15, left‑atrial enlargement, increased LV mass, or invasive hemodynamic confirmation of elevated filling pressures.** The ACC lists these as objective echocardiographic or invasive markers. 12
• Natriuretic peptide concentrations may be modest in HFpEF and can be further suppressed by obesity; therefore, borderline values should not exclude the diagnosis. This caveat is highlighted to avoid false‑negative work‑ups. 11

First‑Line Pharmacologic Therapy

• Initiate an SGLT2 inhibitor (empagliflozin 10 mg daily or dapagliflozin 10 mg daily) in all adults with HFpEF, regardless of diabetes status. The ACC cites robust trial evidence (DELIVER, EMPEROR‑Preserved) showing a 18–23 % relative reduction in HF hospitalizations (HR 0.77–0.82). This is the only drug class with strong morbidity benefit in HFpEF. Strength of evidence: Class I, Level A. 13
• Continue SGLT2‑inhibitor therapy indefinitely unless contraindicated. Ongoing treatment is recommended to sustain benefit. 13

Blood‑Pressure Control

• Target systolic/diastolic blood pressure < 130/80 mmHg (or < 140/90 mmHg in patients ≥ 65 years). The ACC sets these thresholds to reduce afterload and improve outcomes. 13
• Use an ACE inhibitor (e.g., lisinopril) or an ARB (e.g., losartan) as the first‑line antihypertensive agent in HFpEF. These agents effectively achieve BP goals but do not confer the mortality benefit seen in HFrEF. Strength of evidence: Class IIa, Level B. 13

Mineralocorticoid Receptor Antagonist (MRA) Consideration

• Add spironolactone (12.5–25 mg daily) in selected HFpEF patients who have serum potassium < 5.0 mmol/L, creatinine < 2.5 mg/dL, and eGFR > 30 mL/min/1.73 m². The ACC notes modest reduction in HF hospitalizations (HR 0.83) from the TOPCAT trial, without mortality benefit. Strength of evidence: Class IIb, Level B. 13

Management of Key Comorbidities

• Atrial fibrillation: Prioritize ventricular‑rate control and consider rhythm‑control strategies when appropriate. This approach is endorsed by the ACC to mitigate HFpEF symptom burden. Strength of evidence: Class IIa, Level B. 14
• Obesity: Implement supervised weight‑loss programs, as excess weight worsens diastolic dysfunction and HFpEF outcomes. Strength of evidence: Class IIb, Level C. 13
• Diabetes: Utilize SGLT2 inhibitors for dual glycemic and HFpEF benefits, reinforcing their first‑line status. Strength of evidence: Class I, Level A. 13
• Coronary artery disease: Systematically evaluate for ischemia and pursue revascularization when indicated to improve myocardial perfusion and HFpEF symptoms. Strength of evidence: Class IIa, Level B. 13

Referral Recommendations

• Refer to a general cardiologist when diagnostic uncertainty persists after initial evaluation or when exclusion of HFpEF mimics (e.g., infiltrative cardiomyopathy, hypertrophic cardiomyopathy, significant valvular disease, pericardial disease, high‑output states) is required. The ACC outlines these scenarios to ensure accurate phenotyping. [15][16]17
• Refer to a heart‑failure specialist if advanced diagnostic testing (exercise echocardiography, invasive hemodynamics) is needed, if an unusual or complex cardiomyopathy is suspected, or when considering enrollment in clinical trials. These criteria aim to optimize specialized care. [15][11]
• Escalate referral to a specialist when patients exhibit suboptimal response to guideline‑directed medical therapy (GDMT). The ACC recommends specialist input to fine‑tune therapy. 13